Top Markets
#1 Pleasing Gold Pleasing Gold +1,501.47%
#2 Ontology Gas Ontology Gas +118.93%
#3 PulseChain PulseChain +58.72%
#4 Ontology Ontology +36.39%
#5 ConstitutionDAO ConstitutionDAO +31.37%
#6 BOOK OF MEME BOOK OF MEME +31.28%
#7 Neiro Neiro +28.33%
#8 Collect on Fanable Collect on Fanable +27.71%
#9 Pump.fun Pump.fun +23.59%
#10 Unit Pump Unit Pump +23.59%
Coin of the day
Pleasing Gold Pleasing Gold
設定
言語
日本
通貨
USD
テーマ
Edesa Biotech, Inc. Edesa Biotech, Inc.

Edesa Biotech, Inc.

EDSA
株式のランク #25934
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering,... Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
株価
$4.80
時価総額
$46.24M
変化（1日）
-16.52%
変化（1年）
103.39%
国
CA
取引 Edesa Biotech, Inc. (EDSA)

カテゴリー

Healthcare
Edesa Biotech, Inc.（EDSA）の利益
2026 時点の利益 TTM: 0
Edesa Biotech, Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Edesa Biotech, Inc. の利益の推移（2026 〜 2026）
各年末の利益
年 利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US